Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.SK Life Science, the US-based subsidiary of Korean SK Holdings, has selected Patheon as their development services partner for two additional innovative central nervous system drug candidates.
Subscribe to our email newsletter
Patheon will provide formulation and analytical development services as well as clinical supplies for one of the CNS candidates in multiple dosage forms for SK Life Science’s advanced clinical studies.
In addition, Patheon will provide development and clinical materials manufacturing services for another CNS candidate in Phase I clinical trials.
Wes Wheeler, president and CEO of Patheon, said: “This agreement to develop SK Life Science’s two innovative candidates for the treatment of CNS disorders expands upon our existing relationship with the company, having recently completed Phase I development and clinical materials manufacturing for their next generation pain drug candidate.”